News and Press Releases
Press releases
Theralase Launches Seventh US-Based Clinical Study Site and Treats First Patient in the US
Toronto, Ontario – June 11, 2021, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical s...
0Theralase Release FY2020 Audited Financial Statements
Toronto, Ontario – April 28, 2021, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical s...
0
Theralase Releases Quarterly Newsletter
Toronto, Ontario – April 27, 2021, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical st...
0Theralase Commences Collaborative Research with National Microbiology Laboratory for Development of Coronavirus Vaccine
Toronto, Ontario – April 9, 2021, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical sta...
0Theralase launches Anti-Cancer Therapy Research Centre
Toronto, Ontario – March 29, 2021, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical s...
0Theralase Launches Sixth Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study
Toronto, Ontario – March 25, 2021, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical s...
0Theralase Launches Fifth Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study
Toronto, Ontario – February 24, 2021,Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical ...
0Theralase Releases Quarterly Newsletter
Toronto, Ontario – February 01, 2021, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical...
0Theralase Launches Fourth Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study
Toronto, Ontario – January 27, 2021, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical...
0Theralase Launches Third Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study
Toronto, Ontario – January 25, 2021, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical...
0in the news
BTv – Theralase® an innovative medical technology for bladder cancer treatment – 2018
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.
